All In MedTech

Device Trial Radar · NCT05864248

Feasibility Study SA of the Supira System for HRPCI

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

71

Actual

Start

Sep 13, 2023

Primary completion

Feb 6, 2026

Study completion Feb 6, 2026

Sponsor

Lead sponsor
Supira MedicalNot on our public-company list
Sponsor type
Industry
First posted
May 18, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing high-risk percutaneous interventions (HRPCI).

Conditions

  • Heart Diseases
  • Coronary Artery Disease (CAD)
  • Heart Failure

Interventions

  • Supira SystemDevice

    The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Feasibility Endpoint: Successful initiation and maintenance of hemodynamic support without sustained hypotension throughout the index procedure.Time frame: From device delivery through device removal (up to 4 hours).
  2. Primary Safety Endpoint: Rate of composite major device-related adverse events (MDRAEs), from device delivery through device removal.Time frame: From device delivery through device removal (up to 4 hours).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Instituto Dante Pazzanese De Cardiologia (Dante)

    São Paulo, Brazil

  • 'Instituto Do Coração de São Paulo (InCor)'

    São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.